OncoMatch/Clinical Trials/NCT07131319
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Is NCT07131319 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Tislelizumab, Carboplatin, Pemetrexed and Tislelizumab, paclitaxel, Carboplatin for non-small cell lung cancer.
Treatment: Tislelizumab, Carboplatin, Pemetrexed · Tislelizumab, paclitaxel, Carboplatin — The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are: Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07131319 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages